CD44 and PTGS2 Methylation are Independent Prognostic Markers for Biochemical Recurrence Among Prostate Cancer Patients with Clinically Localized Disease

• DOI: 10.4161/epi.1.4.3530
• Publication Date: 2010-06-09T09:36:38Z
• Authors: Karen Woodson; Keith J O’Reilly; David E Ward; Jack Walter; Jeffery Hanson; Elyse L Walk; Joseph A Tangrea
• Keywords: Male; Analysis of Variance; Prostatic Neoplasms; DNA Methylation; Prognosis; 3. Good health; 03 medical and health sciences; Hyaluronan Receptors; 0302 clinical medicine; Cyclooxygenase 2; Biomarkers, Tumor; Linear Models; Humans; Neoplasm Recurrence, Local

Up to 30% of men with clinically localized disease who receive radical prostatectomy develop a biochemical recurrence. Gene methylation in tumor tissue may distinguish men with aggressive cancer. This study evaluated methylation of GSTP1, RARb2, CD44 and PTGS2 with biochemical recurrence among 60 patients who underwent radical prostatectomy using logistic regression and Kaplan Meier time to event analysis. Methylation of GSTP1 and RARbeta2 was not associated with recurrence, however, CD44 and PTGS2 methylation were significant predictors. In multivariate models adjusting for Gleason grade, the methylation profile of CD44 and PTGS2 combined was an independent predictor of biochemical recurrence (associated with 9-fold increased risk). In addition, Kaplan Meier analysis showed CD44 and PTGS2 methylation was associated with shorter time to recurrence. CD44 and PTGS2 methylation may predict biochemical recurrence in prostate cancer patients undergoing radical prostatectomy and if validated in larger studies, may identify patients with aggressive cancer.